James Kihara insider trades: Acadia Pharmaceuticals (ACAD) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where James reports to the SEC
Open-market buys and sales
24 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | ACAD | ↓ Sell | 11,421 | $26.08 | $298K | Direct | Jun 29, 2026 (3d) |
| May 26, 2026 | ACAD | ↓ Sell | 5,401 | $21.18 | $114K | Direct | May 27, 2026 (1d) |
| May 4, 2026 | ACAD | ↓ Sell | 1,332 | $21.79 | $29K | Direct | May 5, 2026 (1d) |
| Apr 7, 2026 | ACAD | ↓ Sell | 1,030 | $22.20 | $23K | Direct | Apr 7, 2026 (0d) |
| Nov 18, 2025 | ACAD | ↓ Sell | 4,084 | $23.69 | $97K | Direct | Nov 19, 2025 (1d) |
| May 16, 2025 | ACAD | ↓ Sell | 4,000 | $22.50 | $90K | Direct | May 19, 2025 (3d) |
| May 2, 2025 | ACAD | ↓ Sell | 1,327 | $14.60 | $19K | Direct | May 2, 2025 (0d) |
| Apr 8, 2025 | ACAD | ↓ Sell | 1,028 | $14.82 | $15K | Direct | Apr 8, 2025 (0d) |
| Mar 26, 2025 | ACAD | ↓ Sell | 1,095 | $17.05 | $19K | Direct | Mar 26, 2025 (0d) |
| Feb 24, 2025 | ACAD | ↓ Sell | 475 | $19.96 | $9K | Direct | Feb 25, 2025 (1d) |
| Nov 19, 2024 | ACAD | ↓ Sell | 4,073 | $16.81 | $68K | Direct | Nov 19, 2024 (0d) |
| May 2, 2024 | ACAD | ↓ Sell | 1,326 | $16.94 | $22K | Direct | May 3, 2024 (1d) |
| Apr 8, 2024 | ACAD | ↓ Sell | 1,790 | $17.87 | $32K | Direct | Apr 9, 2024 (1d) |
| Feb 26, 2024 | ACAD | ↓ Sell | 474 | $24.67 | $12K | Direct | Feb 27, 2024 (1d) |
| Dec 15, 2023 | ACAD | ↓ Sell | 2,000 | $28.30 | $57K | Direct | Dec 15, 2023 (0d) |
| Nov 20, 2023 | ACAD | ↓ Sell | 1,985 | $22.64 | $45K | Direct | Nov 21, 2023 (1d) |
| Sep 15, 2023 | ACAD | ↓ Sell | 2,000 | $25.88 | $52K | Direct | Sep 19, 2023 (4d) |
| Jun 15, 2023 | ACAD | ↓ Sell | 2,000 | $24.15 | $48K | Direct | Jun 16, 2023 (1d) |
| May 17, 2023 | ACAD | ↓ Sell | 5,947 | $22.50 | $134K | Direct | May 19, 2023 (2d) |
| Apr 10, 2023 | ACAD | ↓ Sell | 523 | $18.14 | $9K | Direct | Apr 11, 2023 (1d) |
| Apr 6, 2023 | ACAD | ↓ Sell | 701 | $18.16 | $13K | Direct | Apr 7, 2023 (1d) |
| Feb 24, 2023 | ACAD | ↓ Sell | 350 | $18.78 | $7K | Direct | Feb 27, 2023 (3d) |
| Apr 8, 2022 | ACAD | ↓ Sell | 1,025 | $27.05 | $28K | Direct | Apr 11, 2022 (3d) |
| Feb 23, 2022 | ACAD | ↓ Sell | 359 | $23.80 | $9K | Direct | Feb 25, 2022 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ACAD insiders
Open-market trades in the last 12 months
About James Kihara's insider trades
James Kihara is Principal Accounting Officer at Acadia Pharmaceuticals (ACAD). Since Feb 23, 2022, James has reported no open-market purchases and 24 sales worth $1.2M on SEC Form 4. In the last 12 months: 5 sales ($561K).
Their filings also include option exercises (18 filings), grants and awards (7 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ACAD insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.